MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US

January 22, 2021 Auto Bot ALS, amyotrophic lateral sclerosis, Biotech, License Agreement, Signs, Treat 0

Shots:

  • Aquestive will receive upfront, milestones, royalties on net sales for Exservan (oral film formulation) in the US and will earn revenue pursuant to the exclusive supply agreement
  • MTPA to commercialize Exservan in the US while Aquestive will serve as the exclusive sole manufacturer and supplier for the product
  • Exservan is an oral film formulation of riluzole, expected to be available in the mid of 2021

Click here ­to­ read full press release/ article | Ref: MTPA | Image: PR Newswire

The post MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US first appeared on PharmaShots.